About this Video

• Video Title: Brigham Buhler: The Peptide Safety Data Reveals 75,000+ Patients With Zero Adverse Events |TUH #182
• Channel: Ultimate Human Podcast with Gary Brecka
• Speakers: Gary Brecka, Brigham Buhler
• Duration: 00:22:40

Introduction

This podcast episode features a discussion between Gary Brecka and Brigham Buhler about peptides, their safety, and the potential for wider accessibility. They discuss the FDA's historical relationship with big pharma, the lack of safety data used to justify peptide restrictions, and the significant positive experiences with peptides reported in their practices. The conversation also touches upon the potential of big data, artificial intelligence, and early cancer detection.

Key Takeaways

• Peptides' Safety: Buhler presents data indicating over 75,000 patients using various peptides experienced zero adverse events, contrasting with the FDA's decision to restrict access based on a claimed lack of safety data.
• FDA's Influence: The discussion highlights concerns about the FDA's historical influence by large pharmaceutical companies and the potential for biased information impacting regulatory decisions.
• The "Make America Healthy Again" Movement: The conversation connects peptides and other regenerative modalities to the broader goal of improving health span and lifespan, emphasizing proactive, predictive, and personalized medicine.
• Advocacy Efforts: Buhler details his efforts to communicate with the FDA and present data supporting wider access to peptides and other beneficial treatments. The conversation demonstrates a growing push for transparency and reform within the FDA.
• AI in Healthcare: The potential of AI and big data in early cancer detection and personalized medicine is discussed, illustrating a hopeful future for preventative healthcare.

The transcript does not specify which particular peptides had the 75,000+ patient safety record with zero adverse events. While several peptides are mentioned (BPC-157, TB500, Thymosin alpha, and GLP-1s are explicitly named), the transcript doesn't link these specific examples to the large dataset of patients with no adverse events. More information would be needed to answer this question definitively.